Nutrition and Nonalcoholic Fatty Liver Disease: the Significance of Cholesterol

Overview

Journal Int J Hepatol

Publisher Wiley

Specialty Gastroenterology

Date 2012 May 3

PMID 22550592

Citations 33

Authors

Munechika Enjoji

Kenichiro Yasutake

Motoyuki Kohjima

Makoto Nakamuta

Affiliations

Soon will be listed here.

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a common chronic liver disease that ranges in severity from simple steatosis to cirrhosis. NAFLD is considered to be associated with hepatic metabolic disorders, resulting in overaccumulation of fatty acids/triglycerides and cholesterol. The pathogenesis and progression of NAFLD are generally explained by the "two-hit theory." Most studies of lipid metabolism in the NAFLD liver have focused on the metabolism of fatty acids/triglycerides; therefore, the impact of cholesterol metabolism is still ambiguous. In this paper, we review recent studies on NAFLD from the viewpoint of hepatic lipid metabolism-associated factors and discuss the impact of disordered cholesterol metabolism in the etiology of NAFLD. The clinical significance of managing cholesterol metabolism, an option for the treatment of NAFLD, is also discussed.

Citing Articles

MAFLD: an ideal framework for understanding disease phenotype in individuals of normal weight.

Pan Z, Khatry M, Yu M, Choudhury A, Sebastiani G, Alqahtani S Ther Adv Endocrinol Metab. 2024; 15:20420188241252543.

PMID: 38808010 PMC: 11131400. DOI: 10.1177/20420188241252543.

Extract Prevents Hepatic Steatosis by Enhancing Bile Acid Synthesis in a High-Fat Diet-Induced Fatty Liver Mouse Model.

Kim W, Baek W, Yun S, Lee H, Kim M, Lee S Nutrients. 2024; 16(6).

PMID: 38542804 PMC: 10975839. DOI: 10.3390/nu16060893.

Effects of Egg Consumption on Subjects with SLD or Hypertension: A MICOL Study.

Tatoli R, Bonfiglio C, Cuccaro F, Campanella A, Coletta S, Pesole P Nutrients. 2024; 16(3).

PMID: 38337714 PMC: 10856908. DOI: 10.3390/nu16030430.

Safety evaluation of saffron extracts in early and established atherosclerotic New Zealand white rabbits.

Abd Rahim I, Mohd Kasim N, Omar E, Muid S, Nawawi H PLoS One. 2024; 19(1):e0295212.

PMID: 38207245 PMC: 10783933. DOI: 10.1371/journal.pone.0295212.

The roles of nuclear receptors in cholesterol metabolism and reverse cholesterol transport in nonalcoholic fatty liver disease.

Li Z, Zheng D, Zhang T, Ruan S, Li N, Yu Y Hepatol Commun. 2023; 8(1).

PMID: 38099854 PMC: 10727660. DOI: 10.1097/HC9.0000000000000343.

References

Toshimitsu K, Matsuura B, Ohkubo I, Niiya T, Furukawa S, Hiasa Y . Dietary habits and nutrient intake in non-alcoholic steatohepatitis. Nutrition. 2006; 23(1):46-52. DOI: 10.1016/j.nut.2006.09.004. View

Kainuma M, Fujimoto M, Sekiya N, Tsuneyama K, Cheng C, Takano Y . Cholesterol-fed rabbit as a unique model of nonalcoholic, nonobese, non-insulin-resistant fatty liver disease with characteristic fibrosis. J Gastroenterol. 2006; 41(10):971-80. DOI: 10.1007/s00535-006-1883-1. View

Zelcer N, Tontonoz P . Liver X receptors as integrators of metabolic and inflammatory signaling. J Clin Invest. 2006; 116(3):607-14. PMC: 1386115. DOI: 10.1172/JCI27883. View

Thuy S, Ladurner R, Volynets V, Wagner S, Strahl S, Konigsrainer A . Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J Nutr. 2008; 138(8):1452-5. DOI: 10.1093/jn/138.8.1452. View

Purohit V, Rapaka R, Shurtleff D . Role of cannabinoids in the development of fatty liver (steatosis). AAPS J. 2010; 12(2):233-7. PMC: 2844512. DOI: 10.1208/s12248-010-9178-0. View

You M, Matsumoto M, Pacold C, Cho W, Crabb D . The role of AMP-activated protein kinase in the action of ethanol in the liver. Gastroenterology. 2004; 127(6):1798-808. DOI: 10.1053/j.gastro.2004.09.049. View

Enjoji M, Yada R, Fujino T, Yoshimoto T, Yada M, Harada N . The state of cholesterol metabolism in the liver of patients with primary biliary cirrhosis: the role of MDR3 expression. Hepatol Int. 2009; 3(3):490-6. PMC: 2748377. DOI: 10.1007/s12072-009-9137-y. View

Kashi M, Torres D, Harrison S . Current and emerging therapies in nonalcoholic fatty liver disease. Semin Liver Dis. 2008; 28(4):396-406. DOI: 10.1055/s-0028-1091984. View

Osei-Hyiaman D, Depetrillo M, Pacher P, Liu J, Radaeva S, Batkai S . Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest. 2005; 115(5):1298-305. PMC: 1087161. DOI: 10.1172/JCI23057. View

10.

Turley S, Dietschy J . Sterol absorption by the small intestine. Curr Opin Lipidol. 2003; 14(3):233-40. DOI: 10.1097/00041433-200306000-00002. View

11.

Kohjima M, Enjoji M, Higuchi N, Kato M, Kotoh K, Yoshimoto T . Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. Int J Mol Med. 2007; 20(3):351-8. View

12.

James O, Day C . Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. J Hepatol. 1998; 29(3):495-501. DOI: 10.1016/s0168-8278(98)80073-1. View

13.

Sugimoto T, Yamashita S, Ishigami M, Sakai N, Hirano K, Tahara M . Decreased microsomal triglyceride transfer protein activity contributes to initiation of alcoholic liver steatosis in rats. J Hepatol. 2002; 36(2):157-62. DOI: 10.1016/s0168-8278(01)00263-x. View

14.

Enjoji M, Nakamuta M . Is the control of dietary cholesterol intake sufficiently effective to ameliorate nonalcoholic fatty liver disease?. World J Gastroenterol. 2010; 16(7):800-3. PMC: 2825326. DOI: 10.3748/wjg.v16.i7.800. View

15.

Angulo P . Nonalcoholic fatty liver disease. N Engl J Med. 2002; 346(16):1221-31. DOI: 10.1056/NEJMra011775. View

16.

Matsuzawa N, Takamura T, Kurita S, Misu H, Ota T, Ando H . Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. Hepatology. 2007; 46(5):1392-403. DOI: 10.1002/hep.21874. View

17.

Higuchi N, Kato M, Shundo Y, Tajiri H, Tanaka M, Yamashita N . Liver X receptor in cooperation with SREBP-1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease. Hepatol Res. 2008; 38(11):1122-9. DOI: 10.1111/j.1872-034X.2008.00382.x. View

18.

Nakamuta M, Kohjima M, Morizono S, Kotoh K, Yoshimoto T, Miyagi I . Evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. Int J Mol Med. 2005; 16(4):631-5. View

19.

Hyogo H, Tazuma S, Arihiro K, Iwamoto K, Nabeshima Y, Inoue M . Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism. 2008; 57(12):1711-8. DOI: 10.1016/j.metabol.2008.07.030. View

20.

Kotronen A, Seppala-Lindroos A, Vehkavaara S, Bergholm R, Frayn K, Fielding B . Liver fat and lipid oxidation in humans. Liver Int. 2009; 29(9):1439-46. DOI: 10.1111/j.1478-3231.2009.02076.x. View